Welcome to our dedicated page for Arbutus Biopharm news (Ticker: ABUS), a resource for investors and traders seeking the latest updates and insights on Arbutus Biopharm stock.
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company focused on infectious disease, with a particular emphasis on chronic hepatitis B virus (cHBV) infection. The ABUS news feed highlights company announcements on clinical data, corporate strategy and intellectual property developments that shape the outlook for its pipeline and technology.
Investors and observers following ABUS news can find regular updates on imdusiran (AB-729), Arbutus’ RNAi therapeutic designed to reduce hepatitis B viral proteins and antigens including HBsAg. News items include results from Phase 1 and Phase 2a trials, such as reports of patients achieving what the company describes as functional cure, analyses of HBsAg and HBV DNA reductions, and presentations at major liver disease conferences including the European Association for the Study of the Liver (EASL) Congress and the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting.
The ABUS news stream also covers developments related to AB-101, the company’s oral PD-L1 inhibitor candidate. Releases describe safety, tolerability and pharmacodynamic findings from the ongoing Phase 1a/1b trial in healthy volunteers and cHBV patients, including data on PD-L1 receptor occupancy and the absence of AB-101-related serious adverse events reported to date.
Another recurring theme in Arbutus news is its LNP intellectual property. Joint announcements with Genevant Sciences and company updates detail U.S. and international patent infringement actions against Moderna and Pfizer/BioNTech concerning the use of LNP technology in COVID-19 vaccines. Corporate news also includes board and executive changes, restructuring actions, and strategic decisions such as reacquiring Greater China rights to imdusiran and forming a Scientific Advisory Board of cHBV experts.
For those tracking ABUS stock and the company’s progress in hepatitis B and LNP technology, this news page provides a centralized view of clinical milestones, litigation updates and corporate developments as disclosed by Arbutus in its press releases.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced promising preliminary data from the lead-in phase of its Phase 2a clinical trial for AB-729, targeting chronic Hepatitis B virus (cHBV). With 43 patients enrolled, the initial results show a 1.51 log decline in HBsAg after 16 weeks, similar to Phase 1b results. The treatment, combined with nucleos(t)ide analogue (NA) therapy and Peginterferon alfa-2a, demonstrates a safe profile. The company expects to release further results from the trial's IFN phase in the first half of 2023, underscoring its commitment to addressing chronic HBV infection.
Arbutus Biopharma Corporation (ABUS) reported strong cash reserves of $190.2 million as of September 30, 2022, sufficient to fund operations into Q2 2024. The company showcased promising data on its RNAi therapeutic AB-729, indicating long-term control of HBV biomarkers. Total revenue increased 79% year-over-year to $6.0 million, driven by collaborations. However, the net loss decreased from $24.2 million to $17.6 million, reflecting a loss per share of $0.12. Despite challenges from COVID-19, the company is on track to achieve milestones in its clinical pipeline by year-end.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that CEO William Collier will present at the Jefferies London Healthcare Conference on November 16, 2022, at 11:30 am GMT / 6:30 am EDT. The presentation will be accessible via a live webcast on Arbutus' website, with an archived replay available afterward. Arbutus is focused on developing therapeutics for viral diseases, particularly Hepatitis B and coronaviruses, with key compounds like AB-729 currently in phase 2 clinical trials.
Arbutus Biopharma (ABUS) announced promising findings from clinical trials of its RNAi therapeutic, AB-729, showing sustained HBV suppression in patients up to 44 weeks after treatment cessation. Additionally, preclinical data for AB-101, an oral PD-L1 inhibitor, indicate improved HBV immune response when combined with RNAi therapy. However, the company has halted AB-836 development due to safety concerns. Upcoming poster presentations at the AASLD – The Liver Meeting will detail these findings. A conference call is scheduled for November 4, 2022, to discuss these results.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that it will present three posters with clinical data at the AASLD Liver Meeting 2022 from November 4-8 in Washington, DC. The presentations will cover findings from its lead compound AB-729 and the preclinical PD-L1 inhibitor AB-101. Key data highlights include:
- Long-term HBV control in patients after stopping nucleos(t)ide analogue therapy.
- Increased immune responses in HBV-infected mice with combined treatment.
- Interim analysis of a Phase 2 study showing safety in various treatment combinations.
Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced its schedule for the third quarter 2022 financial results and corporate update, set for November 9, 2022. The press release will be available at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET.
The company focuses on developing therapeutics for viral diseases, including HBV and SARS-CoV-2. Notably, its lead compound AB-729 is undergoing evaluation in multiple phase 2 clinical trials.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that Chief Development Officer Gaston Picchio will depart for personal reasons effective December 31, 2022. The company has begun the search for his successor. CEO William Collier expressed gratitude for Dr. Picchio's contributions, particularly in advancing the clinical pipeline targeting chronic hepatitis B virus (HBV). Arbutus focuses on developing therapeutics aimed at HBV and other viral diseases, including its lead RNAi therapeutic, AB-729, currently in multiple Phase 2 clinical trials.
Arbutus Biopharma Corporation (Nasdaq: ABUS) will participate in a fireside chat at Chardan’s 6th Annual Genetic Medicines Conference on October 4, 2022, at 2:30 pm ET. Key executives, including President & CEO William Collier and Chief Scientific Officer Dr. Michael Sofia, will present. A live webcast is available on the company’s website, and an archived replay will follow. Arbutus focuses on discovering therapeutics for viral diseases, particularly Hepatitis B and SARS-CoV-2, with ongoing phase 2 trials for its lead compound AB-729.
WARMINSTER, Pa., Sept. 06, 2022 – Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in two upcoming investor conferences in New York. They will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13 at 12:30 PM ET, with CEO William Collier as the presenter. Additionally, they will hold a fireside chat at Baird's 2022 Global Healthcare Conference on September 14 at 10:15 AM ET. Live webcasts will be available on their website, with replays accessible post-event.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the issuance of U.S. Patent No. 11,427,823 by the USPTO, granting composition of matter protection for its AB-729 RNAi therapeutic. This patent extends exclusivity for AB-729 until at least April 2038. The company is advancing AB-729 through multiple Phase 2a clinical trials, showing promising safety and efficacy, with significant reductions in hepatitis B surface antigen and DNA levels. Arbutus aims to address the unmet medical needs of over 290 million chronic hepatitis B virus patients globally.